[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ovarian-stimulation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ovarian-stimulation":54},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,40,66,94,121,151],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100580590","follicular-volume-at-the-time-of-final-oocyte-maturation-in-poor-responders-and-its-correlation-with-oocyte-maturity-100580590",false,"NCT06839274","Follicular Volume at the Time of Final Oocyte Maturation in Poor Responders, and Its Correlation With Oocyte Maturity","Inclusion Criteria:\n\n* Reproductive age group: 18 -48\n* undergoing ovarian stimulation for oocyte vetrification\n* undergoing IVF\u002F ICSI with PGT-A \u002F PGT-M \u002F PGT- Sr\n* less than or equal to 3 AFC on initiation of stimulation\n* follicular phase stimulation\n\nExclusion Criteria:\n\n* surgically retrieved sperm",true,"FEMALE","18 Years","48 Years",{"count":20,"type":21},100,"ESTIMATED","30 Months","OBSERVATIONAL","Women with a severely diminished ovarian reserve and monofollicular growth are at a higher risk of premature ovulation as well as poor quality oocytes. Our group showed previously that women with severely diminished ovarian reserve benefit from receiving the final oocyte maturation at smaller follicle sizes in terms of reducing the risk of premature ovulation and finding mature oocytes even out of small size follicles.\n\nAdding the measurement of the follicular volume at the time of final oocyte maturation might provide more information on the proper timing of trigger administration compared to the follicular size alone, hormonal profile as well as previous stimulation attempts. Setting a cutoff value of follicular volume for trigger might help to avoid premature ovulation and possibly increase the chances of ending up with a euploid embryo.",[26],"OVARIAN STIMULATION","RECRUITING","2026-06-22",{"date":30,"type":31},"2026-06-25","ACTUAL",{"date":33,"type":31},"2025-03-27",{"date":35,"type":21},"2026-12-31",{"name":37,"class":38},"ART Fertility Clinics LLC","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":48,"enrollmentInfo":49,"targetDuration":51,"studyType":23,"phases":4,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":60,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":39},"100560114","serum-fsh-monitoring-for-identification-of-an-optimal-range-during-ovarian-stimulation-100560114","NCT06572930","Serum FSH Monitoring for Identification of an Optimal Range During Ovarian Stimulation","Assessment of the Role of Serum FSH Monitoring During Ovarian Stimulation and Identification of an Optimal Range for Expected Normal Responders","FSH","Inclusion Criteria:\n\n* regular 21 - 35 days cycles\n* BMI between 19 - 30 kg\u002Fm2\n* serum AMH level between 1.5 to 3 ng\u002Fml\n* a total antral follicle count between 10 to 24\n* endogenous early follicular phase serum FSH level \\\u003C10 IU\u002FL\n* normal glomerular filtration rate\n\nExclusion Criteria:\n\n* hypogonadotropic hypogonadism\n* history of ovarian surgery\n* permanent ovarian cysts of any form\n* older than 39 years\n* abnormal thyroid stimulating hormone (TSH)\n* renal disease\n* elevated prolactin levels\n* intake of oral contraceptives 3 months before stimulation start and estradiol pretreatment will be excluded","39 Years",{"count":50,"type":21},150,"1 Year","This study examines if monitoring serum Follicle Stimulation Hormone (FSH) levels can predict oocyte yield and progesterone levels, considering factors like age, baseline FSH, Antral Mullerian Hormone (AMH), antral follicle count, body weight, kidney function, and urinary FSH. The aim is to find a minimum FSH level that ensures optimal ovarian response and enables tailored FSH dosages for better outcomes.",[54],"Ovarian Stimulation",[56,57,58,59],"ovarian response","stimulation protocols","stimulation monitoring","follicular stimulating hormone",{"date":30,"type":31},{"date":62,"type":31},"2024-12-16",{"date":64,"type":21},"2026-12-01",{"name":37,"class":38},{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":74,"enrollmentInfo":75,"targetDuration":4,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":93},"100632548","ai-top-study-artificial-intelligence-for-trigger-optimization-100632548","NCT07515118","AI-TOP Study Artificial Intelligence for Trigger Optimization.","An Artificial Intelligence Based Approach for Selecting the Optimal Day for Triggering.","AI-TOP","Inclusion Criteria:\n\n* Undergoing COS for IVF with autologous oocytes, oocyte donation and elective fertility preservation with all monitoring USS (ultrasound scan) conducted at our centers.\n\nExclusion Criteria:\n\n* Medically indicated fertility preservation\n* Inability to attend clinic visits for monitoring.","42 Years",{"count":76,"type":21},644,"INTERVENTIONAL",[79],"NA","To evaluate, in a randomized controlled trial, whether AI-guided monitoring and ovulation triggering leads to clinical outcomes comparable to those achieved through physician-led decision-making in patients undergoing ovarian stimulation for IVF.",[82,54,83],"Infertility","Artificial Intelligence","2026-04-21",{"date":86,"type":31},"2026-04-22",{"date":88,"type":31},"2026-04-08",{"date":90,"type":21},"2027-09",{"name":92,"class":38},"Fundacion Dexeus",5,{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":102,"enrollmentInfo":103,"targetDuration":4,"studyType":77,"phases":105,"briefSummary":107,"conditions":108,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":39},"100529596","phase-4-ppos-progestin-primed-ovarian-stimulation-and-corifollitropin-alfa-cfa-cross-over-study-100529596","NCT06175832","PPOS (Progestin Primed Ovarian Stimulation) and Corifollitropin Alfa (CFA) Cross-over Study","PPOS and CFA for Elective Freeze-all Ovarian Stimulation Cycles: a Prospective Cross-over Study","P-CCROSS","Prescreening: Clarification: Pre-screening might be performed to identify women with AFC \\> 5 and AMH \\> 1.1 ng\u002Fml (Bologna criteria, AFC and AMH values are valid for one year).\n\nInclusion criteria for:\n\n* Group 1: indication for oocyte cryopreservation\n* Group 2: indication for IVF\u002FICSI and PGT-A\n\nInclusion criteria for both groups:\n\n* First ovarian stimulation cycle\n* Aged ≥ 18 and \\\u003C 41 years old at the time of first OPU\n\nExclusion Criteria:\n\n* contra-indication for ovarian stimulation\n* expected poor ovarian response (Bologna Criteria)\n* PCOS patients\n* refusal to fill out questionnaires before, during and after treatment\n* simultaneous participation in another clinical study\n* untreated and uncontrolled thyroid dysfunction;\n* current use of oral contraceptives, anti-psychotics, anti-epileptics or chemotherapy;\n* pregnant or breastfeeding women. A woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming postmenopausal unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause.","40 Years",{"count":104,"type":21},60,[106],"PHASE4","P-CCROSS is a randomized, prospective monocentric phase 4 study with a crossover study design. The aim of the study is to compare patient satisfaction (by means of questionnaires) and treatment compliance with IVF treatment with CFA (corifollitropin alfa) and PPOS (Progestin-Primed Ovarian Stimulation) versus conventional IVF treatment with a recombinant FSH\u002FGnRH antagonist. The study will also compare patients undergoing elective fertility preservation versus PGT-A (pre-implantation genetic testing for aneuploidy) patients.The study will have a crossover design so that patients will receive both forms of treatment. The investigators will also compare the endocrine profile and ovarian response of CFA\u002FPPOS versus rFSH\u002FGnRH ovarian stimulation cycles.",[54,109,110,111],"Quality of Life","Preimplantation Genetic Testing","Fertility Preservation","2025-12-18",{"date":114,"type":31},"2025-12-26",{"date":116,"type":31},"2025-01-27",{"date":118,"type":21},"2027-12-31",{"name":120,"class":38},"University Hospital, Ghent",{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":102,"enrollmentInfo":128,"targetDuration":4,"studyType":77,"phases":129,"briefSummary":130,"conditions":131,"keywords":134,"overallStatus":140,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":150},"100602303","phase-4-optimal-stimulation-of-hypo-responders-undergoing-in-vitro-fertilization-ivf-100602303","NCT07121751","Optimal Stimulation of Hypo-responders Undergoing in Vitro Fertilization (IVF)","Optimal Stimulation of Hypo-responders Undergoing IVF: a Prospective, Randomized, Controlled Trial","Inclusion Criteria:\n\n* indication for IVF-ICSI\n* age 18-40 years\n* \\\u003C9 oocytes in a previous IVF cycle and having an AMH ≥1.2 ng\u002Fml and\u002For AFC ≥5 (POSEIDON 1,2)\n* The use of ≤225 IU FSH (either rFSH alone or the combination of rFSH+hMG) in the previous cycle\n* regular 24-35 day cycles\n* Intact uterine cavity\n* motile sperm from ejaculate or testicular biopsy\n\nExclusion Criteria:\n\n* not meeting the inclusion criteria\n* the use of rFSH:rLH (2:1 ratio) in the previous cycle\n* the use of clomiphene citrate or aromatase inhibitor in the previous cycle\n* \\>225 IU gonadotropin in the previous cycle\n* \\>3 failed previous treatments\n* patient with recurrent miscarriages\n* presence of a hydrosalpinx\n* positive HIV or hepatitis screening test\n* planned preimplantation genetic testing of the embryos\n* planned elective cryopreservation\n* lack of consent",{"count":50,"type":21},[106],"Stimulation is a key step of in vitro fertilization (IVF). Typically, injectable gonadotropins are used for stimulation, and their dose is individually determined to avoid hypo- as well as hyper-response. Despite the individualization some patients respond with a lower-than-expected number of oocytes. If the low response is unexpected based on the baseline parameters or if an unusually high dose of gonadotropins is needed to achieve a proper response we talk about \"hypo-response\". In such cases if the first treatment fails and a repeat attempt is planned typically even more gonadotropins, the combination of luteinizing hormone (LH) with follicle stimulating hormone (FSH) or the use of the more potent recombinant preparations are considered. The benefits of these approaches however have not been studied properly in hypo-responders. The studies have used various criteria to identify hypo-responders, have used various gonadotropin doses and have evaluated different outcome parameters. Live birth was only studied in one trial.\n\nIt is also known that in a different cycle the same patient is likely to have a slightly different response to the same type and dose of drugs. Therefore, the question arises whether a hypo-responder in one treatment is expected to have hypo-response again if the treatment is similarly carried out in a different cycle. Do we need to change\u002F increase the gonadotropin dose if based on age and ovarian reserve otherwise we would expect a normal response? Furthermore, if we consider a change should we increase the dose of FSH or should we combine it with LH?\n\nTherefore the aim of this randomized controlled trial is compare an unchanged medication regimen to increased dose of FSH vs the combination of FSH and LH in hypo-responder patients identified based on POSEIDON (Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number) criteria (Gr 1 and 2: retrieval of 9 or fewer oocytes in patients with an anti-Müllerian hormone (AMH) level ≥ 1.2 ng\u002Fml or antral follicle count (AFC) ≥ 5 and age \\\u003C35 years \\[Group (Gr) 1\\] or ≥35 years \\[Gr2\\]). Hypo-responder patients will be randomized to:\n\n1. Same gonadotropin dose as in previous treatment (recombinant(r) FSH) \\['control group'\\]\n2. The same dose as in the previous cycle but in the form of FSH + LH combination (rFSH:rLH 2:1 ratio) \\['additional LH group'\\]\n3. A dose increase of 75 international unit (IU) compared to the dose in the previous treatment. \\['higher dose FSH group'\\] The primary outcome parameter to study is live clinical pregnancy. In addition, baseline demographic, stimulation and further clinical outcomes (pregnancy rate, miscarriage rate, live birth rate) will be compared.",[132,133,26],"Hypo-responder","Infertility (IVF Patients)",[135,136,137,138,139],"ovarian stimulation","in vitro fertilization","hypo-responder","gonadotropin","luteinizing hormone","NOT_YET_RECRUITING","2025-08-10",{"date":143,"type":31},"2025-08-13",{"date":145,"type":21},"2025-09-01",{"date":147,"type":21},"2027-03-01",{"name":149,"class":38},"Dunamenti REK Istenhegyi IVF Center",4,{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":155,"acronym":156,"eligibilityCriteria":157,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":158,"enrollmentInfo":159,"targetDuration":161,"studyType":23,"phases":4,"briefSummary":162,"conditions":163,"keywords":166,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":39},"100572405","does-recombinant-fsh-rfsh-ig-gonal-f-as-compared-to-human-menopausal-gonadotrophin-hmg-affect-telomere-length-of-cumulus-cells-during-antral-follicle-growth-and-impact-blastocyst-status-100572405","NCT06732843","Does Recombinant FSH (rFSH, i.g. Gonal F®) as Compared to Human Menopausal Gonadotrophin (hMG) Affect Telomere Length of Cumulus Cells During Antral Follicle Growth and Impact Blastocyst Status?","rFSH and hMG","Inclusion Criteria:\n\n1. Maternal age 18 - 38 years\n2. Patients requested PGT-A\n3. BMI 18- 30kg\u002Fm2\n4. Expected normoresponders\n5. Fresh autologous ejaculate (≥5 mill\u002Fml)\n6. Sperm abstinence: 2-3 days\n7. Normal female\u002Fmale karyotype\n8. Regular menstrual cycle length: 25-32 days\n9. AFC of 5-10 in each ovary at the beginning of the stimulation\n10. Trigger: dual trigger: 2.500 IU urinary hCG + 0.3 mg Decapeptyl. (13)\n11. A wash-out period between 1 to 3 months; an inter-cycle variation of 10% in AFC, measured by the same physician, is accepted.\n12. Couple agrees to perform two stimulations before continuing with embryo transfer\n\nExclusion Criteria:\n\n* 1\\. Uterine abnormalities as diagnosed by ultrasound 2. Any hormonal or oral contraceptive pretreatment of 3 months preceding the treatment 3. Endometriosis according to American Fertility Society (AFS) ≥3 4. ≥ 2 miscarriages 5. Bologna criteria poor responders (14)","38 Years",{"count":160,"type":21},10,"60 Months","Gonal-F® (follitropin alfa) is a recombinant FSH without LH activity, while Menopur® contains both LH and hCG. The MEGASET trial compared Menopur® and Gonal-F® in GnRH antagonist cycles with SET, showing similar efficacy. A subsequent study (MEGASET-HR) in high responders found ongoing pregnancy rates of 35.5% for Menopur® and 30.7% for Gonal-F®, with a lower early pregnancy loss for Menopur® (14.5% vs 25.5%).\n\nTelomere length (TL) in oocyte cumulus cells (CC) correlates with oocyte quality and embryo outcomes. This study aims to assess whether stimulation type (hMG vs. Gonal-F) affects TL in CC and subsequent blastocyst development. A randomized, open-label, cross-over study in normo-responders will analyze telomere length, embryo quality, and hormonal markers.",[26,164,165],"Telomere Length","Telomere Length, Mean Leukocyte",[167,168,169,170,171,172,173,174,175,176],"recombinant human follicle-stimulating hormone (rFSH)","uman-menopausal-gonadotropin (hMG","ocyte quality","embryo quality","blastocyst development","Menopur","GonalF","GnRH antagonist cycles","trophectoderm","cumulus cells","2025-07-24",{"date":179,"type":31},"2025-07-25",{"date":181,"type":31},"2025-07-23",{"date":183,"type":21},"2027-07-31",{"name":37,"class":38}]